Feng, Y., Xiao, Yy., Li, Sd. et al. The treatment of non-small cell lung cancer by interstitial I-125 seeds implantation combined with chemotherapy and Chinese medicine., Chin. J. Integr. Med. 18, 663–669 (2012). https://doi.org/10.1007/s11655-012-1203-y
Yu Feng, Yue-yong Xiao, Shao-dan Li, et al. The treatment of non-small cell lung cancer by interstitial I-125 seeds implantation combined with chemotherapy and Chinese medicine[J]. Chinese Journal of Integrative Medicine, 2012,18(9):663-669.
Feng, Y., Xiao, Yy., Li, Sd. et al. The treatment of non-small cell lung cancer by interstitial I-125 seeds implantation combined with chemotherapy and Chinese medicine., Chin. J. Integr. Med. 18, 663–669 (2012). https://doi.org/10.1007/s11655-012-1203-yDOI:
Yu Feng, Yue-yong Xiao, Shao-dan Li, et al. The treatment of non-small cell lung cancer by interstitial I-125 seeds implantation combined with chemotherapy and Chinese medicine[J]. Chinese Journal of Integrative Medicine, 2012,18(9):663-669. DOI: 10.1007/s11655-012-1203-y.
The treatment of non-small cell lung cancer by interstitial I-125 seeds implantation combined with chemotherapy and Chinese medicine
摘要
To investigate the effects of brachytherapy with computed tomography-guided percutaneous radioactive I-125 seeds interstitial implantation (ISI) synchronized chemotherapy and Chinese medicine (CM) for the treatment of advanced stage of non-small cell lung cancer (NSCLC). Ninety patients diagnosed with NSCLC by biopsy were randomly assigned to three groups: the synchronized therapy group (A)
the chemotherapy plus CM-treated group (B)
and the chemotherapy-treated group (C); a 2-month course of treatment was administered to them all. The effectiveness of treatment was evaluated based on tumor size
tumor markers (carcinoembryonic
squamous cell carcinoma-associated antigen
and cytokeratin 19 fragment)
clinical symptoms
and quality of life (QOL) in patients. The total effective rates of Groups A to C were 83.33%
46.67%
and 43.33%
respectively. The tumor markers were reduced obviously in Group A
showing signifificant difference compared with those in the other two groups. Additionally
QOL was elevated and cancer-related symptoms were alleviated more signifificant in Group A than those in Group C (all P<0.05). The synchronized therapy of I-125 implantation with chemotherapy and CM was a safe therapeutic method and can be regarded as a new mode for treatment of advanced-stage NSCLC.
Abstract
To investigate the effects of brachytherapy with computed tomography-guided percutaneous radioactive I-125 seeds interstitial implantation (ISI) synchronized chemotherapy and Chinese medicine (CM) for the treatment of advanced stage of non-small cell lung cancer (NSCLC). Ninety patients diagnosed with NSCLC by biopsy were randomly assigned to three groups: the synchronized therapy group (A)
the chemotherapy plus CM-treated group (B)
and the chemotherapy-treated group (C); a 2-month course of treatment was administered to them all. The effectiveness of treatment was evaluated based on tumor size
tumor markers (carcinoembryonic
squamous cell carcinoma-associated antigen
and cytokeratin 19 fragment)
clinical symptoms
and quality of life (QOL) in patients. The total effective rates of Groups A to C were 83.33%
46.67%
and 43.33%
respectively. The tumor markers were reduced obviously in Group A
showing signifificant difference compared with those in the other two groups. Additionally
QOL was elevated and cancer-related symptoms were alleviated more signifificant in Group A than those in Group C (all P<0.05). The synchronized therapy of I-125 implantation with chemotherapy and CM was a safe therapeutic method and can be regarded as a new mode for treatment of advanced-stage NSCLC.
关键词
advanced non-small cell lung cancerradioactive particlebrachytherapychemotherapyChinese Medicine
Keywords
advanced non-small cell lung cancerradioactive particlebrachytherapychemotherapyChinese Medicine
references
Zou XN. Epidemiology of lung cancer in China. Chin Cancer Prevent Treat 2007;14:881–883.
Modern oncology. 2nd ed. Shanghai: Shanghai Medical University Press; 2000:877.
Berhoune M, Banu E, Scotte F, Prognon P, Oudard S, Bonan B. Therapeutic strategy for treatment of metastatic non-small cell lung cancer. Ann Pharmacother 2008;42:1640–1652.
Zheng XY. Guiding principle for clinical research on new drugs of traditional Chinese medicine. Beijing: China medicine science Press; 2002:217–218.
China Association of Chinese Medicine. Chinese guideline for the diagnosis and treatment of tumor. Beijing: China Press of Traditional Chinese Medicine; 2008:9–12.
Sun Y, Shi YK, eds. Manual of clinical oncology. Beijing: People’s Medical Publishing House; 2010:147–157.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European organization for research and treatment of cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365–376.
Luo KY. The utility of interstitial implantation brachytherapy in treatment of malignant cancer. Beijing: People’s Medical Publishing House; 2008:49–77.
Cui YL, Yang G, Wang Y. The clinic value of CT-guided interstitial 125I seeds implantation for lung cancer. J Harbin Med Univ (Chin) 2008;42:400–402.
Zhang ZH. The clinic value of CT-guided interstitial 125I seeds implantation for 20 lung cancer patinets. Chin J Coal Industry Med (Chin) 2010;2:249.
Tian GY, Zhang L. CT-guided interstitial implantation of 125I seeds for non-small cell lung cancer. J Interventional Radiol (Chin) 2009;18:704–707.
Mo SX. The clinic value of CT-guided interstitial 125I seeds implantation with hyperthermia and chemotherapy for the phase III of lung cancer. Guangdong Med J (Chin) 2010;31:781–783.
Dan G, Li W, Zhao TJ, Xue P, Zhang HF, LU R. The observation of tumor markers after 125I seed implantation in the treatment of non small cell lung cancer. Med J National Defending Forces Southwest China (Chin) 2009;19:220–222.
Wang C, Wang L, Shu Q. Clinical observation of Matrine Injection combined with TP project in treatment of non small cell lung cancer. Lab Med Clin (Chin) 2010;7:1681–1682.
Wu J, Xu ZY, Wang ZQ, Zhou WD, Deng HB, Zhao XZ, et al. Clinical study on treatment of advanced non-small cell lung cancer with Kangliu Zengxiao Decoction. Chin J Integr Tradit West Med (Chin) 2010;30:137–140.
Zhang PT, Yu MW, Yang ZY, Li DR, Liu YH, Lin HS. Comparative study on the methods of Chinese medicine and Western medicine therapeutic evaluation for advanced non-small cell lung cancer. Chin J Integr Tradit West Med (Chin) 2010;30:702–705.
Shi F, Jia XB, Jia DS, Chen Y, Huang Y, Xu QM. Research of material base of Hedyotis diffusa Willd. in preventing lung cancer. China J Tradit Chin Med Pharm (Chin) 2010;25:403–408.
Wang H, Xu SF, Zhao FJ. The research progress of Scutellaria barbate D. Don on anti-cancer effect and its mechanism. J Minzu Univ China (Natural Sci, Chin) 2010;19(4):77–80.
Huang CH, Lu Y, Sun ZG, Chen L, Zhang L. Advances in studies on anti-cancer mechanism of Curcumae Rhizoma. Chin Tradit Herbal Drugs (Chin) 2010;41:1745–1747.
Chen HT, Zhu HX, Liu ZQ, Wang HB, Li Z, Yu BQ, et al. Effect of clinical observation of Danggui Buxue Decoction on tumor patients after chemotherapy. J Hebei Med Coll Continuing Education (Chin) 2008, 25(5):54–55.
Wang JH, Ren HY, Yu Y. Clinical observation of Xiaoleiwan with Erchen prescription on the sublingual gland cyst. China Modern Med (Chin) 2010;170(7):83–84.
Liu TZ, Zhang L, Wang QF, Feng FF, Nie GJ, Wu WC, et al. Diagnostic value of combined determination of serum CEA, NSE, SCC-Ag and CYFRA21-1 for lung cancer. J Zhengzhou Univ (Med Sci, Chin) 2010;45:809–811.
Wang CH, Chen MX, Zhang CZ, Tang XL, Meng Q, Zhang XQ, et al. Cancer patients quality of life scale for evaluation of Chinese version of EORTC QLQ-C30. J Practical Oncol (Chin) 2005;20:353–355.
Aronson NK, Cull A, Keasa S. The European Organization for Research and Treatment of Cancer (EORTC) modular approach to quality of life assessment in oncology. Int J Ment Health 1994;23:75–96.
Anonymous. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999;91:66–72.
Xue D, Li PP. Clinical benefits as endpoints in advanced non-small cell lung cancer treated with integrative medicine. Chin J Integr Med 2011;17:228–231.
Yiqi Zhuyu Decoction (益气逐瘀汤) Combined with FOLFOX-4 as first-line therapy in metastatic colorectal cancer
In Vitro and In Vivo inhibitory effect of the combination of Wenxia Changfu Formula (温下肠腑方) with cisplatin in non-small cell lung cancer
Effects of combined Chinese drugs and chemotherapy in treating advanced non-small cell lung cancer
Clinical observation of Shuanghuang Shengbai Granule (双黄升白颗粒) on prevention and treatment of myelosuppression caused by chemotherapy in cancer patients
Comprehensive treatment with Chinese medicine in patients with advanced non-small cell lung cancer: A multicenter, prospective, cohort study
相关作者
暂无数据
相关机构
Department of Colorectal and Anal Surgery, the First Affiliated Hospital of Guiyang College of Traditional Chinese Medicine
Department of Colorectal Surgery, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Colorectal Cancer Center of Shanghai Jiaotong University
School of Basic Medical Science, Shandong University of Traditional Chinese Medicine
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Integration Traditional Chinese and Western Medicine, Peking University School of Oncology, Beijing Cancer Hospital & Institute
Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine